Andrew Hope
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrew Hope has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Ali Hosni
Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada
3 shared publications - B.C. John Cho
Department of Radiation Oncology, the Princess Margaret Cancer Centre/University of Toronto, Canada
3 shared publications - Ezra Hahn
Department of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Canada
3 shared publications - Andrew McPartlin
Radiation Medicine Program, Princess Margaret Cancer Centre, University of Toronto, 610 University Ave, Toronto, ON M5G 2M9, Canada
2 shared publications - Anna Spreafico
Division of Medical Oncology, the Princess Margaret Cancer Centre/University of Toronto, Canada
2 shared publications - Benjamin Haibe-Kains
Princess Margaret Cancer Center, University Health Network
2 shared publications
Latest Publications
- 26 August 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (9) , 898
Quality assurance and improvement in dental oncology
- 26 August 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (9) , 898
Quality assurance and improvement in dental oncology
- Open Access
- 6 June 2026
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 39
Auto-segmentation of organs-of-interest clinical acceptability & reproducibility framework in head and neck cancer
- 6 June 2026
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 39
Open AccessAuto-segmentation of organs-of-interest clinical acceptability & reproducibility framework in head and neck cancer
- 22 April 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 220, 111546
Cardiac adverse events following post-operative radiation therapy in patients with thymic malignancies
- 22 April 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 220, 111546
Cardiac adverse events following post-operative radiation therapy in patients with thymic malignancies
- Open Access
- 17 September 2025
- Published by Elsevier in Technical Innovations & Patient Support in Radiation Oncology
- Vol. 36, 100345
A prospective audit of thoracic reirradiation practice and peer-review in a high-volume academic center
- 17 September 2025
- Published by Elsevier in Technical Innovations & Patient Support in Radiation Oncology
- Vol. 36, 100345
Open AccessA prospective audit of thoracic reirradiation practice and peer-review in a high-volume academic center
- Open Access
- 3 September 2025
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 50, 101218
Risk factors and survival impact of severe radiation-related late toxicities in head and neck cancer–a cohort study
- 3 September 2025
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 50, 101218
Open AccessRisk factors and survival impact of severe radiation-related late toxicities in head and neck cancer–a cohort study
- Open Access
- 30 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-10
Measured intrapatient radiomic variability as a predictor of treatment response in multi-metastatic soft tissue sarcoma patients
Radiomics offers a non-invasive approach to tumor characterization, yet its application in metastatic cancers is limited by intertumor heterogeneity—variability in radiomic phenotypes across lesions within the same patient. We introduce Measured Intrapatient Radiomic Variability (MIRV), a novel metric quantifying heterogeneity using standard-of-care imaging. Applied to 397 metastatic soft-tissue sarcoma patients from the SARC021 trial, MIRV was calculated from pretreatment CT scans using pairwise Euclidean distance and cosine dissimilarity between lesions. Euclidean distance captures absolute differences in radiomic features, while cosine dissimilarity assesses variation in feature patterns independent of magnitude. Higher MIRV correlated with greater variability in tumor-specific response classification and volumetric response, independent of baseline tumor volume. In a subset with liquid biopsy data, MIRV showed a moderate association with ctDNA positivity, suggesting links to molecular heterogeneity. While MIRV was not prognostic for overall survival in the full cohort, higher MIRV was significantly associated with worse survival in leiomyosarcoma patients (n = 165, p = 0.007, FDR = 0.06). These findings establish MIRV as a biomarker for intertumor heterogeneity, with potential to predict mixed treatment responses and guide personalized therapy in metastatic STS. Future studies should assess its relevance across other tumor types and therapeutic settings.
- 30 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-10
Open AccessMeasured intrapatient radiomic variability as a predictor of treatment response in multi-metastatic soft tissue sarcoma patients
Radiomics offers a non-invasive approach to tumor characterization, yet its application in metastatic cancers is limited by intertumor heterogeneity—variability in radiomic phenotypes across lesions within the same patient. We introduce Measured Intrapatient Radiomic Variability (MIRV), a novel metric quantifying heterogeneity using standard-of-care imaging. Applied to 397 metastatic soft-tissue sarcoma patients from the SARC021 trial, MIRV was calculated from pretreatment CT scans using pairwise Euclidean distance and cosine dissimilarity between lesions. Euclidean distance captures absolute differences in radiomic features, while cosine dissimilarity assesses variation in feature patterns independent of magnitude. Higher MIRV correlated with greater variability in tumor-specific response classification and volumetric response, independent of baseline tumor volume. In a subset with liquid biopsy data, MIRV showed a moderate association with ctDNA positivity, suggesting links to molecular heterogeneity. While MIRV was not prognostic for overall survival in the full cohort, higher MIRV was significantly associated with worse survival in leiomyosarcoma patients (n = 165, p = 0.007, FDR = 0.06). These findings establish MIRV as a biomarker for intertumor heterogeneity, with potential to predict mixed treatment responses and guide personalized therapy in metastatic STS. Future studies should assess its relevance across other tumor types and therapeutic settings.
- 23 August 2024
- Published by Elsevier in Oral Oncology
- Vol. 158, 107007
The prognostic value of image-identified extranodal extension in laryngeal and hypopharyngeal carcinoma following definitive (chemo-)radiotherapy
- 23 August 2024
- Published by Elsevier in Oral Oncology
- Vol. 158, 107007
The prognostic value of image-identified extranodal extension in laryngeal and hypopharyngeal carcinoma following definitive (chemo-)radiotherapy
- Open Access
The [18F]F-FDG PET/CT Radiomics Classifier of Histologic Subtypes and Anatomical Disease Origins across Various Malignancies: A Proof-of-Principle Study
We aimed to investigate whether [18F]F-FDG-PET/CT-derived radiomics can classify histologic subtypes and determine the anatomical origin of various malignancies. In this IRB-approved retrospective study, 391 patients (age = 66.7 ± 11.2) with pulmonary (n = 142), gastroesophageal (n = 128) and head and neck (n = 121) malignancies were included. Image segmentation and feature extraction were performed semi-automatically. Two models (all possible subset regression [APS] and recursive partitioning) were employed to predict histology (squamous cell carcinoma [SCC; n = 219] vs. adenocarcinoma [AC; n = 172]), the anatomical origin, and histology plus anatomical origin. The recursive partitioning algorithm outperformed APS to determine histology (sensitivity 0.90 vs. 0.73; specificity 0.77 vs. 0.65). The recursive partitioning algorithm also revealed good predictive ability regarding anatomical origin. Particularly, pulmonary malignancies were identified with high accuracy (sensitivity 0.93; specificity 0.98). Finally, a model for the synchronous prediction of histology and anatomical disease origin resulted in high accuracy in determining gastroesophageal AC (sensitivity 0.88; specificity 0.92), pulmonary AC (sensitivity 0.89; specificity 0.88) and head and neck SCC (sensitivity 0.91; specificity 0.92). Adding PET-features was associated with marginal incremental value for both the prediction of histology and origin in the APS model. Overall, our study demonstrated a good predictive ability to determine patients’ histology and anatomical origin using [18F]F-FDG-PET/CT-derived radiomics features, mainly from CT.
Open AccessThe [18F]F-FDG PET/CT Radiomics Classifier of Histologic Subtypes and Anatomical Disease Origins across Various Malignancies: A Proof-of-Principle Study
We aimed to investigate whether [18F]F-FDG-PET/CT-derived radiomics can classify histologic subtypes and determine the anatomical origin of various malignancies. In this IRB-approved retrospective study, 391 patients (age = 66.7 ± 11.2) with pulmonary (n = 142), gastroesophageal (n = 128) and head and neck (n = 121) malignancies were included. Image segmentation and feature extraction were performed semi-automatically. Two models (all possible subset regression [APS] and recursive partitioning) were employed to predict histology (squamous cell carcinoma [SCC; n = 219] vs. adenocarcinoma [AC; n = 172]), the anatomical origin, and histology plus anatomical origin. The recursive partitioning algorithm outperformed APS to determine histology (sensitivity 0.90 vs. 0.73; specificity 0.77 vs. 0.65). The recursive partitioning algorithm also revealed good predictive ability regarding anatomical origin. Particularly, pulmonary malignancies were identified with high accuracy (sensitivity 0.93; specificity 0.98). Finally, a model for the synchronous prediction of histology and anatomical disease origin resulted in high accuracy in determining gastroesophageal AC (sensitivity 0.88; specificity 0.92), pulmonary AC (sensitivity 0.89; specificity 0.88) and head and neck SCC (sensitivity 0.91; specificity 0.92). Adding PET-features was associated with marginal incremental value for both the prediction of histology and origin in the APS model. Overall, our study demonstrated a good predictive ability to determine patients’ histology and anatomical origin using [18F]F-FDG-PET/CT-derived radiomics features, mainly from CT.
- Open Access
Exploring the Language Used to Describe Older Patients at Multidisciplinary Cancer Conferences
Older adults with cancer often present with distinct complexities that complicate their care, yet the language used to discuss their management at multidisciplinary cancer conferences (MCCs) remains poorly understood. A mixed methods study was conducted at a tertiary cancer centre in Toronto, Canada, where MCCs spanning five tumour sites were attended over six months. For presentations pertaining to a patient aged 75 or older, a standardized data collection form was used to record their demographic, cancer-related, and non-cancer-related information, as well as the presenter’s specialty and training level. Descriptive statistics and thematic analysis were employed to explore MCC depictions of older patients (n = 75). Frailty status was explicitly mentioned in 20.0% of presentations, but discussions more frequently referenced comorbidity burden (50.7%), age (33.3%), and projected treatment tolerance (30.7%) as surrogate measures. None of the presentations included mentions of formal geriatric assessment (GA) or validated frailty tools; instead, presenters tended to feature select GA domains and subjective descriptions of appearance (“looks to be fit”) or overall health (“relatively healthy”). In general, MCCs appeared to rely on age-focused language that may perpetuate ageism. Further work is needed to investigate how frailty and geriatric considerations can be objectively incorporated into discussions in geriatric oncology.
Open AccessExploring the Language Used to Describe Older Patients at Multidisciplinary Cancer Conferences
Older adults with cancer often present with distinct complexities that complicate their care, yet the language used to discuss their management at multidisciplinary cancer conferences (MCCs) remains poorly understood. A mixed methods study was conducted at a tertiary cancer centre in Toronto, Canada, where MCCs spanning five tumour sites were attended over six months. For presentations pertaining to a patient aged 75 or older, a standardized data collection form was used to record their demographic, cancer-related, and non-cancer-related information, as well as the presenter’s specialty and training level. Descriptive statistics and thematic analysis were employed to explore MCC depictions of older patients (n = 75). Frailty status was explicitly mentioned in 20.0% of presentations, but discussions more frequently referenced comorbidity burden (50.7%), age (33.3%), and projected treatment tolerance (30.7%) as surrogate measures. None of the presentations included mentions of formal geriatric assessment (GA) or validated frailty tools; instead, presenters tended to feature select GA domains and subjective descriptions of appearance (“looks to be fit”) or overall health (“relatively healthy”). In general, MCCs appeared to rely on age-focused language that may perpetuate ageism. Further work is needed to investigate how frailty and geriatric considerations can be objectively incorporated into discussions in geriatric oncology.
- 1 December 2021
- Published by Elsevier in Oral Oncology
- Vol. 123, 105604
Clinical practice guidelines for dental management prior to radiation for head and neck cancer
- 1 December 2021
- Published by Elsevier in Oral Oncology
- Vol. 123, 105604
Clinical practice guidelines for dental management prior to radiation for head and neck cancer